INmune BioINMB
Recorded

INmune Bio 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration25 minParticipants6

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Greetings, and welcome to INmune Bio's 2026 third quarter earnings call. As a reminder, this conference is being recorded. A transcript will follow within 24 hours of this conference call. in this meeting, there will be no question-and-answer session. Should you have any inquiries, please email them to Mr. Dan Carlson. It is my pleasure to introduce Mr. Dan Carlson, Head of Investor Relations of INmune Bio.

Daniel CarlsonHead of Investor Relations

Dan? Thank you, operator, and good afternoon, everyone.

Daniel CarlsonHead of Investor Relations

We thank you for joining us for the call for INmune Bio's third quarter 2026 financial results. Presenting on today's call are David Moss, CEO and co-founder of INmune Bio, Dr. Mark Lowdell, Chief Scientific Officer and co-founder of INmune Bio, and Cory Ellspermann, INmune Bio CFO. Before we begin, I remind everyone that except for statements of historical fact, the statements made by management and responses to questions on this conference call are forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that can cause actual results to differ materially from those expressed or implied by such forward-looking statements.

Daniel CarlsonHead of Investor Relations

Please see the forward-looking statements disclaimer in the company's earnings press release, as well as risk factors in the company's SEC filings, including our most recent quarterly filings with the SEC. There is no assurance of any specific outcome. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made, as the facts and circumstances underlying these forward-looking statements may change. Except as required by law, INmune Bio disclaims any obligation to update these forward-looking statements to reflect future information, events, or circumstances. Now, my pleasure to turn the call over to INmune Bio CEO, David Moss.

David MossCEO and Co-Founder

Thank you, Dan, and good afternoon, everyone. Thank you for joining us for INmune Bio's third quarter 2026 earnings call. This is an exciting time for INmune Bio. We're getting close to important milestones of entering a new phase in the company's development as we move Ebstrocel towards regulatory approval and prepare to make it available to patients. During the quarter, we made important progress in manufacturing, regulatory preparation, and international patient expansion. Each of these steps brings us closer to our goal of transforming INmune Bio from a clinical-stage company into a commercial-stage company. The immediate focus is on execution as we're getting very close. This involves assembling the complete regulatory package, establishing a practical route to patient access, and carefully allocating capital to these milestones. I want to be clear about our confidence in these activities.

David MossCEO and Co-Founder

We believe the clinical data presents a compelling case for Ebstrocel as a potentially first-in-class systemic treatment in RDEB. Importantly, Ebstrocel addresses the top concerns from RDEB patients: itch, pain, inflammation, and wounds. Combined with the progress we've made in manufacturing and our discussions with regulators, we believe we're in a strong position as we move towards approval. Of course, the final decisions rest with the regulatory agencies, but our confidence in the program remains very high. Today, I will review our strategy and capital priorities, including how we intend to advance XPro after we've had regulatory clarity on Ebstrocel. Mark will then discuss Ebstrocel's approval process and commercial readiness. Cory will review our financial results, and I will return to summarize the milestones ahead before we take your questions. Before I discuss our regulatory timelines, I want to introduce Alex Hersham, whose child lives with RDEB.

David MossCEO and Co-Founder

Alex has kindly agreed to join us today to share his perspective as a father and what this disease means for his family. Alex recently visited our manufacturing center in Stevenage and met with the team working on Ebstrocel. For all of us at INmune Bio, hearing directly from families gives our work a deep personal meaning. Behind every clinical endpoint and regulatory milestone is a child, a parent, and a family hoping for a better day's life. Every member of our team, whether in the laboratory, in manufacturing, and across the company, has a role in advancing that goal and shares this mission wholeheartedly. That responsibility gives us urgency and purpose. Our job is to bring the same care and determination to develop potential treatments that families bring to caring for their children every day. Alex, thank you for being here and sharing your family's experience.

David MossCEO and Co-Founder

I'll turn it over to you.

Alex HershamFounder

My son, Abe, is three and a half and has severe recessive dystrophic EB. People tend to think of EB as a skin disease, but day-to-day, it's much more than that. It's his skin, his eyes, and his esophagus. It's itch, pain, constant inflammation, and the exhaustion that comes with all of it. Living with EB means huge stress and a real risk of trauma for him and for us. The daily rhythm is hard, baths are tough, dressing changes are long, and he understandably hates them. Every day starts and ends with care that no two-year-old should have to sit through. VYJUVEK has been a meaningful improvement for Abe. He's been on it for almost three years. It's made a real difference to his wounds, and we're glad to have it. But it's one piece of a much bigger picture.

Alex HershamFounder

His eyes are still a very large challenge, although there are a few therapies coming down the track. We need wounds that close longer, and we need better answers for his itch, the inflammation, and his energy. The itch is truly cruel. It is the main cause of his large wounds, including wounds that VYJUVEK had already closed. He scratches, the skin opens, and we start again. Some families have found certain biologics helpful, but nothing works for everyone, and nothing helps consistently. The damage does not stop at the wounds. More wounds means more inflammation, which drives more itch. It takes his sleep, his energy, and so much of his quality of life and ours. A treatment that could genuinely calm the itch and the inflammation behind it would change our lives. That is why continued investment in new approaches matters so much to families like ours.

David MossCEO and Co-Founder

Thank you, Alex, for sharing your family's experience with us. Hearing from you reinforces why this work matters so much to every employee at INmune Bio. We know that families are counting on progress, and our responsibility is to bring urgency, care, and scientific rigor to every step, from manufacturing to regulatory submission, and ultimately, patient access. Your perspective stays with us as we make those decisions. With that purpose in mind, let me turn to the progress we are making with Ebstrocel and the milestones ahead. We remain on track to complete a U.K. marketing authorization application in early February 2027, with potential U.K. approval by the middle of the year. We are also targeting a U.S. BLA application mid-2027, subject to feedback from our planned FDA interaction. We are prioritizing the U.S. application ahead of an EMA submission.

David MossCEO and Co-Founder

Focusing on the U.K. approval first is important, given this is where we currently have patients waiting for the drug, which Mark will talk about shortly. The trial was completed in the two leading centers that treat RDEB patients, Great Ormond Street Hospital and Birmingham Children's Hospital. Nearly all the patients from the trial are currently waiting to enroll in a confirmation trial, and we have additional patients also seeking treatment. The Uniphar agreement supports that same objective. It gives us a framework to pursue named patient access in selected European and Middle Eastern and North African markets, with the ability to expand the relationship by agreement. Where local rules permit, physicians may be able to request Ebstrocel for eligible patients before local marketing approval or broad commercial availability. We view our partnership with Uniphar as an important commercial validation of the opportunity we are preparing to address.

David MossCEO and Co-Founder

It brings an experienced international access and distribution organization alongside Ebstrocel as we move towards commercialization. That is a meaningful step in preparation for this program to be a commercial success. Equally important, named patient supplies could provide an earlier source of revenue while awaiting separate approvals and full commercial launches in every country. With Uniphar's sales and distribution network providing the backbone, we believe named patient sales have the potential to become a meaningful source of revenue as access develops. The timing and scale will depend on country-specific implementation, physician requests, lawful supply agreements, and funding or reimbursement. Thus, we are not announcing a revenue forecast or a date for first sales today. Uniphar's existing capability also allow us to pursue these opportunities without building a complete commercial organization country by country. That matters for a company of our size.

David MossCEO and Co-Founder

We want our spending to support regulatory execution, reliable supply, and access for patients. While Ebstrocel is clearly our top priority, we remain very enthusiastic about XPro's long-term potential. Our confidence is grounded in the important role that TNF plays in inflammatory diseases. Broad TNF inhibitors such as HUMIRA, ENBREL, and Remicade have collectively generated hundreds of billions of dollars in sales in their lifetime. We believe XPro's selective inhibition of soluble TNF offers an opportunity to address diseases where inflammation plays a central role, while potentially offering advantages over traditional TNF inhibitors. Our strategy is to identify a disease driven by the biology XPro targets, with a clearly identifiable patient population and outcomes that can be addressed efficiently in a suitable rare disease that could support a smaller, faster, and more capital-efficient development program than a large Alzheimer's trial.

David MossCEO and Co-Founder

Qualifying rare pediatric indications may also offer an additional opportunity through the FDA's Priority Review Voucher Program. Our objective is to identify a program that could reach an approval decision and potentially a voucher on a substantially shorter development timeline. A voucher would be awarded only with a qualifying FDA approval and satisfaction of the applicable requirements and program deadlines. We have not yet selected an indication or established a clinical or regulatory timeframe for this work. Our collaboration with Quantum Computing Inc. is intended to guide us through that selection process more efficiently. We have years of preclinical research and data from our clinical trials. Our collaboration will use optimization, artificial intelligence, and conventional analytics to examine these datasets alongside public biomedical information and identify diseases, patient population, and biomarkers that warrant further investigation.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day